GLP-1 Muscle Loss Study Will Track DXA Scans and Grip Strength

What is the new GLP-1 muscle loss study measuring?

The study was posted to ClinicalTrials.gov on September 22 under the identifier NCT07835360, with the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City listed as sponsor. Its stated purpose is to describe what happens to muscle and fat in adults with obesity, type 2 diabetes, or both after they begin a GLP-1 receptor agonist. The registration lists a target enrollment of 200 participants, with roughly 168 adults expected to take part across two centers.

The registration is unusually explicit about what the study is not. It is not a drug trial. No experimental medication is administered. Investigators plan to follow people who are already starting treatment or having a dose adjusted as part of their ordinary medical care, and the registration states that the study will not change or interfere with any decision made by a participant's own doctor.

The primary measurement tool is dual-energy X-ray absorptiometry, or DXA — a low-dose scan that separates body mass into fat, lean soft tissue and bone rather than reporting a single weight. Participants will be followed for about one year. Alongside the scans, the protocol adds grip strength, walking speed and tests of everyday physical performance, which together give a functional read on whether any lean mass change translates into something a person would notice.

Why lean mass became the question for GLP-1 receptor agonists

GLP-1 receptor agonists — the class that includes semaglutide, dulaglutide and liraglutide, and, in its dual GLP-1/GIP form, tirzepatide — produce weight loss substantially by reducing appetite and food intake. Any large energy deficit, whatever produces it, tends to remove some lean tissue along with fat. The open question has never been whether lean mass falls at all, but how much of it falls, in whom, and whether it matters for strength and daily function.

That distinction is the reason DXA and functional testing appear together in this registration. A scale cannot tell a person whether a given number of kilograms came from fat or from muscle, and body composition is rarely measured in routine weight-management care. The registration frames the concern directly: some weight loss can come from muscle instead of fat, and losing muscle can affect strength and daily function over time.

Two other registrations posted in the same window point at adjacent questions. A Jan Kochanowski University study, NCT07650149, plans to enroll 200 consecutive patients to examine how genetic markers, gut microbiome composition and behavioral factors relate to tolerance, adherence and effectiveness of dual GLP-1/GIP receptor agonist therapy in obesity. A completed 150-participant randomized trial at Zagazig University, NCT07834398, compared dulaglutide, semaglutide and tirzepatide in non-diabetic adults with a BMI above 30 over six months, with weight, BMI, lipids and liver function as its endpoints.

Because this study follows people through routine care rather than a controlled schedule, adherence tracking is one of the variables that separates a real-world cohort from a registration trial.

A review in Maturitas by Pereira, Ishikura, Tufik and colleagues groups the clinical implications of semaglutide in postmenopausal women under weight loss, muscle health and sleep-disordered breathing. a review in Maturitas.

What the Maturitas review adds on semaglutide and muscle health

A review indexed in PubMed from the journal Maturitas, by Pereira, Ishikura, Tufik and colleagues, addresses semaglutide in postmenopausal women and groups its clinical implications under three headings: weight loss, muscle health and sleep-disordered breathing. As a narrative review rather than a trial, it synthesizes existing literature; it does not generate new outcome data, and readers should weigh it accordingly.

The population matters to the muscle question. Postmenopausal women already face age- and hormone-related declines in lean mass and bone density, which is why a review aimed at that group treats muscle health as a named clinical consideration rather than a footnote to weight loss. Sleep-disordered breathing, the review's third heading, is closely tied to body weight and has become an area of active investigation across the incretin class.

Grouping these two items together is the point. One is a review flagging muscle health as a question worth asking in a specific population; the other is a prospective observational study built to measure it with scans and strength testing. Neither one delivers an answer yet.

Perceived changes in strength or stamina sit naturally in the same record as side-effect logging, which gives a provider a timeline rather than a single recalled impression.

Eli Lilly's phase 3 tirzepatide morbidity and mortality study enrolled 15,374 adults with obesity and is listed as active but no longer recruiting.

What an observational study can and cannot establish

Because NCT07835360 follows people who are already being prescribed these drugs in routine care, it cannot separate the effect of the medication from the characteristics of the people who receive it. Patients who start and remain on GLP-1 receptor agonists differ systematically from those who do not — in access, in comorbidity, in baseline activity — and no amount of careful measurement inside a single-arm cohort fully removes that.

What the design can do is describe magnitude and variation in a real-world setting, including in patients who would be excluded from a registration trial. It can also show whether DXA-measured lean mass change tracks with measured grip strength and gait speed, which is a more useful question than lean mass change on its own. Two centers and roughly 168 participants is a modest sample, and results should be read as hypothesis-generating.

Body composition is also absent from the largest trials in the class. Eli Lilly's phase 3 study of tirzepatide in adults with obesity, NCT05556512, enrolled 15,374 participants and is listed as active but no longer recruiting; its stated aim is reduction in morbidity and mortality, not lean mass. That gap between what the big trials power for and what patients ask about is precisely the space smaller studies like this one are trying to fill.

If you are deciding where to keep weight, strength notes and dosing history together, our comparison of peptide tracker apps covers what each tool actually records.

What happens next

The Mexico City study is listed as recruiting, so results are at minimum a year away from completion of follow-up and longer from publication. Until then, nothing in this registration changes what is known; it documents that a group of investigators considers the question important enough to measure directly with imaging rather than inferring it from weight.

Readers should also note the limits of the available record here. The Maturitas paper is indexed with a title and author list but the full text was not available in the material reviewed for this article, and the ClinicalTrials.gov entries describe planned or completed procedures rather than reported findings. Neither source supports any conclusion about how much lean mass any individual loses on any particular agent.

According to the study registration on ClinicalTrials.gov, investigators will use DXA scans over about one year alongside grip strength and walking speed tests in adults starting GLP-1 receptor agonist therapy.